Modifying risk factors: do the means justify the ends?

Stephen B Hanauer

doi:10.1038/ncpgasthep1229 | Full Text | PDF (98K)

Degree of visceral sensation can help determine treatment in IBS patients with bloating

doi:10.1038/ncpgasthep1210 | Full Text | PDF (74K)

Patients with IBS have increased numbers of capsaicin-receptor nerve fibers

doi:10.1038/ncpgasthep1211 | Full Text | PDF (74K)

Characteristics of chronic pancreatitis in primary hyperparathyroidism

doi:10.1038/ncpgasthep1212 | Full Text | PDF (87K)

Fluvastatin inhibits HCV replication in patients who do not respond to PEG-IFN therapy

doi:10.1038/ncpgasthep1213 | Full Text | PDF (78K)

Interleukin 21 is important for the T-helper cell type 1 response in celiac disease

doi:10.1038/ncpgasthep1214 | Full Text | PDF (88K)

Increased prevalence of HBV infection in patients with type 2 diabetes

doi:10.1038/ncpgasthep1215 | Full Text | PDF (76K)

Moderate wine drinking might decrease prevalence of nonalcoholic fatty liver disease

doi:10.1038/ncpgasthep1216 | Full Text | PDF (76K)

Hypnosis reduces measures of inflammation in patients with active ulcerative colitis

doi:10.1038/ncpgasthep1217 | Full Text | PDF (79K)

The multicomponent approach is a promising strategy for H. pylori vaccine development

doi:10.1038/ncpgasthep1218 | Full Text | PDF (79K)

Liver resection with salvage transplantation for hepatocellular carcinoma

doi:10.1038/ncpgasthep1219 | Full Text | PDF (89K)

Transgastric peritoneoscopy and liver biopsy is feasible in humans

doi:10.1038/ncpgasthep1220 | Full Text | PDF (75K)

Cardiac dysfunction during liver transplantation is common and not predicted by tests

doi:10.1038/ncpgasthep1221 | Full Text | PDF (84K)

Risk of cardiac damage in patients with upper gastrointestinal bleeding

doi:10.1038/ncpgasthep1222 | Full Text | PDF (74K)

Family history influences post-treatment survival in patients with advanced colon cancer

doi:10.1038/ncponc1199 | Full Text | PDF (74K)

Should urgent ERCP be performed in patients with acute biliary pancreatitis without acute cholangitis?

John Baillie

doi:10.1038/ncpgasthep1202 | Full Text | PDF (122K)

Is rosiglitazone a promising treatment for ulcerative colitis?

Andrew N Milestone, Marietta Iacucci and Subrata Ghosh

doi:10.1038/ncpgasthep1226 | Full Text | PDF (130K)

Should patients undergoing ERCP be placed in the prone or supine position?

C Mel Wilcox

doi:10.1038/ncpgasthep1199 | Full Text | PDF (119K)

How useful is capsule endoscopy for the selection of patients for double-balloon enteroscopy?

Shabana F Pasha and Jonathan A Leighton

doi:10.1038/ncpgasthep1201 | Full Text | PDF (119K)

Is radiofrequency ablation the treatment of choice for patients with small hepatocellular carcinoma?

Ronnie TP Poon

doi:10.1038/ncpgasthep1204 | Full Text | PDF (127K)

Is telbivudine superior to lamivudine for the treatment of patients with chronic hepatitis B?

Maria Buti

doi:10.1038/ncpgasthep1205 | Full Text | PDF (119K)

What is the potential role of antifibrotic agents for the treatment of liver disease?

Bernd Schnabl, David Scholten and David A Brenner

Liver fibrosis is characterized by the excessive deposition of extracellular matrix proteins, and results from chronic liver disease. The most important goal of antifibrotic therapy is to remove the fibrogenic stimulus by treating the underlying etiology of liver disease. The authors of this Viewpoint article discuss the promising targets for antifibrotic therapy that have been identified using animal models of liver fibrosis.

doi:10.1038/ncpgasthep1200 | Full Text | PDF (123K)

Leukocytapheresis for the treatment of IBD

Fridrik Thor Sigurbjörnsson and Ingvar Bjarnason

Leukocytapheresis is a controversial nonpharmacologic treatment for IBD, in which white blood cells—the effector cells of the inflammatory process—are mechanically removed from the circulation. The authors of this Review discuss the rationale behind using leukocytapheresis, how it works in practice, its efficacy in patients with IBD and its current standing within guidelines for the treatment of IBD.

doi:10.1038/ncpgasthep1209 | Full Text | PDF (205K)

Esophageal cancer: epidemiology, pathogenesis and prevention

Sarah B Umar and David E Fleischer

The incidence and mortality of esophageal cancer have increased over the past two decades. Research into risk factors plus the ability to identify precursor lesions has permitted studies of chemoprevention for esophageal cancer to be performed; however, esophageal cancer continues to have a poor prognosis. In this Review, the authors focus on the epidemiology, risk factors, pathogenesis and prevention of both esophageal squamous cell carcinoma and esophageal adenocarcinoma.

doi:10.1038/ncpgasthep1223 | Full Text | PDF (256K)

A case of herpes esophagitis after fluticasone propionate for eosinophilic esophagitis

Guy M Lindberg, Richard Van Eldik and Mohammad H Saboorian

This article considers the case of a 19-year-old white woman who presented with a 6-month history of progressively worsening dysphagia. Eosinophilic esophagitis was diagnosed and a PPI and fluticasone propionate prescribed; fluticasone propionate was tapered, but the PPI maintained. When dysphagia returned, fluticasone propionate was restarted, but rapidly progressive dysphagia with severe chest pain and odynophagia developed. A diagnosis of herpes esophagitis with concurrent eosinophilic esophagitis was made, fluticasone propionate treatment immediately discontinued and fluconazole and valaciclovir prescribed.

doi:10.1038/ncpgasthep1225 | Full Text | PDF (384K)